SCM Lifescience Co., Ltd. (KOSDAQ: 298060)
South Korea
· Delayed Price · Currency is KRW 1,948.00
-142.00 (-6.79%)
Dec 20, 2024, 9:00 AM KST
SCM Lifescience Income Statement
Financials in millions KRW. Fiscal year is January - December.
Millions KRW. Fiscal year is Jan - Dec.
Fiscal Year | TTM | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | 2018 - 2014 |
|---|---|---|---|---|---|---|---|
Period Ending | Sep '24 Sep 30, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 | Dec '20 Dec 31, 2020 | Dec '19 Dec 31, 2019 | 2018 - 2014 |
| Operating Revenue | 889.44 | 695.7 | 395.98 | 439.26 | 320.01 | 168.5 | Upgrade
|
| Other Revenue | -0 | - | - | -0 | - | - | Upgrade
|
| Revenue | 889.44 | 695.7 | 395.98 | 439.26 | 320.01 | 168.5 | Upgrade
|
| Revenue Growth (YoY) | 59.52% | 75.69% | -9.85% | 37.27% | 89.92% | 485.85% | Upgrade
|
| Cost of Revenue | 477.4 | 379.54 | 245.84 | 134.82 | 94.2 | 78.99 | Upgrade
|
| Gross Profit | 412.04 | 316.16 | 150.14 | 304.44 | 225.8 | 89.51 | Upgrade
|
| Selling, General & Admin | 4,112 | 3,875 | 3,209 | 1,493 | 7,089 | 4,709 | Upgrade
|
| Research & Development | 7,855 | 9,315 | 9,311 | 10,473 | 8,846 | 7,321 | Upgrade
|
| Other Operating Expenses | 41.79 | 32.18 | 43.73 | 92.69 | 26.77 | 1.16 | Upgrade
|
| Operating Expenses | 12,099 | 13,314 | 12,729 | 12,460 | 16,315 | 12,292 | Upgrade
|
| Operating Income | -11,687 | -12,998 | -12,579 | -12,155 | -16,089 | -12,202 | Upgrade
|
| Interest Expense | -176.69 | -312.57 | -238.79 | -197.63 | -507.54 | -3,487 | Upgrade
|
| Interest & Investment Income | 245.12 | 86.83 | 246.86 | 202.12 | 178.69 | 507.43 | Upgrade
|
| Earnings From Equity Investments | -3,691 | -10,673 | -11,650 | -9,999 | 9,186 | -5,934 | Upgrade
|
| Currency Exchange Gain (Loss) | - | 0.71 | 2.07 | -2.66 | -69.65 | -69.07 | Upgrade
|
| Other Non Operating Income (Expenses) | -18.04 | -6.54 | -11.44 | -3.99 | -2,113 | -19,913 | Upgrade
|
| EBT Excluding Unusual Items | -15,327 | -23,902 | -24,230 | -22,156 | -9,415 | -41,097 | Upgrade
|
| Gain (Loss) on Sale of Investments | -60.83 | -59.16 | 1,300 | -362.15 | -216.46 | -1,457 | Upgrade
|
| Gain (Loss) on Sale of Assets | -259.04 | - | - | -0.48 | -1.38 | - | Upgrade
|
| Pretax Income | -15,647 | -23,961 | -22,930 | -22,519 | -9,633 | -42,554 | Upgrade
|
| Net Income | -15,647 | -23,961 | -22,930 | -22,519 | -9,633 | -42,554 | Upgrade
|
| Net Income to Common | -15,647 | -23,961 | -22,930 | -22,519 | -9,633 | -42,554 | Upgrade
|
| Shares Outstanding (Basic) | 20 | 16 | 15 | 12 | 11 | 5 | Upgrade
|
| Shares Outstanding (Diluted) | 20 | 16 | 15 | 12 | 11 | 5 | Upgrade
|
| Shares Change (YoY) | 37.71% | 12.84% | 21.21% | 12.79% | 101.51% | 58.63% | Upgrade
|
| EPS (Basic) | -763.98 | -1464.07 | -1581.00 | -1882.00 | -908.00 | -8083.00 | Upgrade
|
| EPS (Diluted) | -763.98 | -1464.07 | -1581.00 | -1882.00 | -908.00 | -8083.00 | Upgrade
|
| Free Cash Flow | -13,120 | -12,372 | -11,689 | -14,080 | -12,370 | -17,696 | Upgrade
|
| Free Cash Flow Per Share | -640.57 | -755.92 | -805.93 | -1176.70 | -1165.98 | -3361.24 | Upgrade
|
| Gross Margin | 46.33% | 45.45% | 37.92% | 69.31% | 70.56% | 53.12% | Upgrade
|
| Operating Margin | -1313.92% | -1868.29% | -3176.64% | -2767.18% | -5027.71% | -7241.70% | Upgrade
|
| Profit Margin | -1759.22% | -3444.23% | -5790.66% | -5126.47% | -3010.19% | -25254.54% | Upgrade
|
| Free Cash Flow Margin | -1475.05% | -1778.30% | -2951.85% | -3205.28% | -3865.43% | -10501.86% | Upgrade
|
| EBITDA | -10,894 | -12,158 | -11,538 | -11,020 | -14,858 | -11,039 | Upgrade
|
| D&A For EBITDA | 792.35 | 839.44 | 1,041 | 1,136 | 1,231 | 1,163 | Upgrade
|
| EBIT | -11,687 | -12,998 | -12,579 | -12,155 | -16,089 | -12,202 | Upgrade
|
| Advertising Expenses | - | 278.13 | 146.98 | 217.7 | 148.49 | 107.78 | Upgrade
|
Source: S&P Capital IQ. Standard template. Financial Sources.